Results 71 to 80 of about 24,009 (265)

Case series: Joubert syndrome and eosinophilic esophagitis

open access: yesJPGN Reports, EarlyView.
Abstract Joubert syndrome (JS) is a rare genetic disorder characterized by developmental abnormalities, particularly in the brainstem and cerebellar vermis, alongside multisystem manifestations such as kidney and liver anomalies, polydactyly, cleft lip or palate, and tongue defects.
Jonathon Schening   +5 more
wiley   +1 more source

Impact of Long-Term Proton Pump Inhibitor Therapy on Gut Microbiota in F344 Rats: Pilot Study

open access: yesGut and Liver, 2016
Background/Aims To evaluate changes in gut microbiota composition following long-term proton pump inhibitor (PPI) treatment. Methods : Twenty-four-week-old F344 rats were fed diets with (n=6) or without (n=5) lansoprazole for 50 weeks.
Cheol Min Shin   +11 more
doaj   +1 more source

Non Helicobacter Pylori - Duodenal Ulcer in a Liver Cirrhosis Patient [PDF]

open access: yes, 2002
Peptic ulcer is an clearly marginated ulceration in mucosal membran that can penetrate until muscularis layer and resulted from imbalance between aggressive factor (gastric acid and pepsin) and defensive factor (gastric mucous, bicarbonate and ...
Achmad, H. (Haryono)   +1 more
core   +1 more source

Cryptococcid Sweet Syndrome in the Setting of Hydralazine‐Induced ANCA Vasculitis: A Case Report

open access: yesJournal of Cutaneous Pathology, EarlyView.
ABSTRACT Acute febrile neutrophilic dermatosis, also known as Sweet syndrome, is an inflammatory skin condition characterized by the rapid onset of painful, erythematous plaques or nodules with neutrophilic infiltrate on histology. Rarely, acellular bodies surrounded by vacuolated spaces have been noted within the neutrophilic infiltrate, mimicking ...
Jenna Vroman   +4 more
wiley   +1 more source

Pretreatment of Garlic Oil Extracts Hampers Epithelial Damage in Cell Culture Model of Peptic Ulcer Disease

open access: yesMedicina, 2022
Background and Objectives: Peptic ulcer disease is a chronic disease affecting up to 10% of the world’s population. Proton pump inhibitors, such as lansoprazole are the gold standard in the treatment of ulcer disease.
Lucija Kuna   +9 more
doaj   +1 more source

Vonoprazan vs lansoprazole for the treatment of artificial gastric ulcer after endoscopic submucosal dissection: a prospective randomized comparative study

open access: yesJournal of clinical biochemistry and nutrition, 2020
Vonoprazan is a potent inhibitor of gastric acid secretion and may have better response than proton pump inhibitors (PPIs) in the treatment of endoscopic submucosal dissection induced artificial ulcers. However, reported outcomes remain controversial. In
Hiromitsu Ban   +7 more
semanticscholar   +1 more source

NSAID ingestion augments training‐induced muscle hypertrophy and differentially affects muscle mRNA expression, but not strength gains, in trained men

open access: yesThe Journal of Physiology, EarlyView.
Abstract figure legend Schematic outlining the impact of NSAID ingestion on resistance exercise training‐induced changes in muscle morphology, function and gene networks relative to placebo ingestion in trained males. Abstract Non‐steroidal anti‐inflammatory drugs (NSAIDs) are widely overused in sports.
Joanne E. Mallinson   +6 more
wiley   +1 more source

Safe use of proton pump inhibitors in patients with cirrhosis [PDF]

open access: yes, 2018
Aims: Proton pump inhibitors (PPIs) belong to the most frequently used drugs, also in patients with cirrhosis. PPIs are extensively metabolized by the liver, but practice guidance on prescribing in cirrhosis is lacking.
Borgsteede, S.D. (Sander)   +10 more
core   +2 more sources

Pharmacogenomic testing and its future in community pharmacy [PDF]

open access: yes, 2020
Although it is common to see pharmacogenomic testing used North America and Australia, it is not yet part of practice in the UK. With the promise of genomic screening becoming part of the NHS, pharmacists must equip themselves with a knowledge of how the
Wright, David, Youssef, Essra
core   +1 more source

Olmesartan‐induced gastritis with no lower gastrointestinal symptoms: A case report

open access: yesDEN Open, Volume 6, Issue 1, April 2026.
Abstract A 74‐year‐old man with decreased appetite, weight, and heartburn was referred to our hospital. His medications included olmesartan. Esophagogastroduodenoscopy (EGD) revealed antral‐dominant erosive gastritis and nodular mucosa. A gastric biopsy revealed inflammatory cell infiltration.
Satoshi Kosaka   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy